Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accounts Payables: 2017-2025

Historic Accounts Payables for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $6.7 million.

  • Dianthus Therapeutics' Accounts Payables fell 11.45% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 11.45%. This contributed to the annual value of $4.6 million for FY2024, which is 75.44% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Accounts Payables stood at $6.7 million for Q3 2025, which was up 24.07% from $5.4 million recorded in Q2 2025.
  • Dianthus Therapeutics' 5-year Accounts Payables high stood at $8.3 million for Q1 2025, and its period low was $813,000 during Q2 2023.
  • In the last 3 years, Dianthus Therapeutics' Accounts Payables had a median value of $3.7 million in 2024 and averaged $4.1 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Accounts Payables tumbled by 75.66% in 2023, and later surged by 453.10% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Accounts Payables (Quarterly) stood at $1.2 million in 2022, then soared by 123.65% to $2.6 million in 2023, then surged by 75.44% to $4.6 million in 2024, then fell by 11.45% to $6.7 million in 2025.
  • Its Accounts Payables stands at $6.7 million for Q3 2025, versus $5.4 million for Q2 2025 and $8.3 million for Q1 2025.